Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functions

Molecular Immunology

Volumn 54, Issue 3-4, 2013, Pages 355-367

  Chen, Gang ^a   Panicker, Sandip ^a   Lau, Kai Yeung ^a   Apparsundaram, Subramaniam ^a   Patel, Vaishali A ^a   Chen, Shiow Ling ^a   Soto, Rothschild ^a   Jung, Jimmy K C ^a   Ravindran, Palanikumar ^a   Okuhara, Dayne ^b   Bohnert, Gary ^b   Che, Qinglin ^b   Rao, Patricia E ^b   Allard, John D ^a   Badi, Laura ^a   Bitter, Hans Marcus ^a   Nunn, Philip A ^a   Narula, Satwant K ^a   DeMartino, Julie A ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b Synta Pharmaceuticals Corp   (United States)

Author keywords

CRAC; Gene expression; T cell

Indexed keywords

2,6 DIFLUORO N [5 [4 METHYL 1 (5 METHYL THIAZOL 2 YL) 1,2,5,6 TETRAHYDRO PYRIDIN 3 YL]PYRAZIN 2 YL]BENZAMIDE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL 1; CYCLOSPORIN A; RO 2959; STROMAL INTERACTION MOLECULE 1; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THAPSIGARGIN; UNCLASSIFIED DRUG; YM 58483;

ARTICLE; CALCIUM CURRENT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; ELECTROPHYSIOLOGY; FLUORESCENCE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MEASUREMENT; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANILIDES; ANIMALS; CALCINEURIN; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CYCLOSPORINE; CYTOKINES; GENE EXPRESSION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MEMBRANE PROTEINS; NEOPLASM PROTEINS; RATS; RECEPTORS, ANTIGEN, T-CELL; TACROLIMUS; THIADIAZOLES;

EID: 84873875478     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.12.011     Document Type: Article

References (44)

1. Altman A., Coggeshall K.M., Mustelin T. Molecular events mediating T cell activation. Advances in Immunology 1990, 48:227-360.
2. Beeton C., Pennington M.W., Wulff H., Singh S., Nugent D., Crossley G., Khaytin I., Calabresi P.A., Chen C.Y., Gutman G.A., Chandy K.G. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Molecular Pharmacology 2005, 67:1369-1381.
3. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., Kolski-Andreaco A., Wei E., Grino A., Counts D.R., Wang P.H., LeeHealey C.J., Andrews B.S., Sankaranarayanan A., Homerick D., Roeck W.W., Tehranzadeh J., Stanhope K.L., Zimin P., Havel P.J., Griffey S., Knaus H.G., Nepom G.T., Gutman G.A., Calabresi P.A., Chandy K.G. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:17414-17419.
4. Bergmeier W., Oh-Hora M., McCarl C.A., Roden R.C., Bray P.F., Feske S. R93W mutation in Orai1 causes impaired calcium influx in platelets. Blood 2009, 113:675-678.
5. Byun M., Abhyankar A., Lelarge V., Plancoulaine S., Palanduz A., Telhan L., Boisson B., Picard C., Dewell S., Zhao C., Jouanguy E., Feske S., Abel L., Casanova J.L. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. Journal of Experimental Medicine 2010, 207:2307-2312.
6. De Windt A., Rai M., Kytomaki L., Thelen K.M., Lutjohann D., Bernier L., Davignon J., Soini J., Pandolfo M., Laaksonen R. Gene set enrichment analyses revealed several affected pathways in Niemann-Pick disease type C fibroblasts. DNA and Cell Biology 2007, 26:665-671.
7. 2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. Journal of immunology (Baltimore, Md: 1950) 2009, 183:3454-3462.
8. Djuric S.W., BaMaung N.Y., Basha A., Liu H., Luly J.R., Madar D.J., Sciotti R.J., Tu N.P., Wagenaar F.L., Wiedeman P.E., Zhou X., Ballaron S., Bauch J., Chen Y.W., Chiou X.G., Fey T., Gauvin D., Gubbins E., Hsieh G.C., Marsh K.C., Mollison K.W., Pong M., Shaughnessy T.K., Sheets M.P., Smith M., Trevillyan J.M., Warrior U., Wegner C.D., Carter G.W. 3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator. Journal of Medicinal Chemistry 2000, 43:2975-2981.
9. Fanger C.M., Rauer H., Neben A.L., Miller M.J., Rauer H., Wulff H., Rosa J.C., Ganellin C.R., Chandy K.G., Cahalan M.D. Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. Journal of Biological Chemistry 2001, 276:12249-12256.
10. Feske S. CRAC channelopathies. Pflugers Archiv 2010, 460:417-435.
11. Feske S., Draeger R., Peter H.H., Eichmann K., Rao A. The duration of nuclear residence of NFAT determines the pattern of cytokine expression in human SCID T cells. Journal of Immunology 2000, 165:297-305.
12. Feske S., Draeger R., Peter H.H., Rao A. Impaired NFAT regulation and its role in a severe combined immunodeficiency. Immunobiology 2000, 202:134-150.
13. Feske S., Giltnane J., Dolmetsch R., Staudt L.M., Rao A. Gene regulation mediated by calcium signals in T lymphocytes. Nature Immunology 2001, 2:316-324.
14. Feske S., Gwack Y., Prakriya M., Srikanth S., Puppel S.H., Tanasa B., Hogan P.G., Lewis R.S., Daly M., Rao A. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 2006, 441:179-185.
15. + channel gating in T cells from immunodeficient patients. Journal of Experimental Medicine 2005, 202:651-662.
16. Feske S., Skolnik E.Y., Prakriya M. Ion channels and transporters in lymphocyte function and immunity. Nature Reviews Immunology 2012, 12:532-547.
17. Ghanshani S., Wulff H., Miller M.J., Rohm H., Neben A., Gutman G.A., Cahalan M.D., Chandy K.G. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. Journal of Biological Chemistry 2000, 275:37137-37149.
18. Grgic I., Wulff H., Eichler I., Flothmann C., Kohler R., Hoyer J. Blockade of T-lymphocyte KCa3.1 and Kv1.3 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplantation Proceedings 2009, 41:2601-2606.
19. He L.P., Hewavitharana T., Soboloff J., Spassova M.A., Gill D.L. A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2. Journal of Biological Chemistry 2005, 280:10997-11006.
20. 2+ influx and IL-2 production in T lymphocytes. Journal of Immunology 2003, 170:4441-4449.
21. Keller A., Backes C., Lenhof H.-P. Computation of significance scores of unweighted Gene Set Enrichment Analyses. BMC Bioinformatics 2007, 8:290.
22. Lioudyno M.I., Kozak J.A., Penna A., Safrina O., Zhang S.L., Sen D., Roos J., Stauderman K.A., Cahalan M.D. Orai1 and STIM1 move to the immunological synapse and are up-regulated during T cell activation. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:2011-2016.
23. 2+ channels with distinct functional properties. Current Biology 2007, 17:794-800.
24. 2+ entry cause immunodeficiency, myopathy, and ectodermal dysplasia. Journal of Allergy and Clinical Immunology 2009, 124. 1311-1318e7.
25. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., Laurila E., Houstis N., Daly M.J., Patterson N., Mesirov J.P., Golub T.R., Tamayo P., Spiegelman B., Lander E.S., Hirschhorn J.N., Altshuler D., Groop L.C. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genetics 2003, 34:267-273.
26. 2+ channels. Journal of Biological Chemistry 2008, 283:31348-31355.
27. Nicolaou S.A., Neumeier L., Peng Y., Devor D.C., Conforti L. The Ca(2+)-activated K(+) channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes. American Journal of Physiology - Cell Physiology 2007, 292:C1431-C1439.
28. 2+ entry blocker, on T cell-mediated immune responses in vivo. International Immunopharmacology 2008, 8:1787-1792.
29. + channels in T lymphocytes. European Biophysics Journal 2005, 34:515-529.
30. Panyi G., Bagdany M., Bodnar A., Vamosi G., Szentesi G., Jenei A., Matyus L., Varga S., Waldmann T.A., Gaspar R., Damjanovich S. Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:2592-2597.
31. Panyi G., Vamosi G., Bacso Z., Bagdany M., Bodnar A., Varga Z., Gaspar R., Matyus L., Damjanovich S. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:1285-1290.
32. Panyi G., Varga Z., Gaspar R. Ion channels and lymphocyte activation. Immunology Letters 2004, 92:55-66.
33. Picard C., McCarl C.A., Papolos A., Khalil S., Luthy K., Hivroz C., LeDeist F., Rieux-Laucat F., Rechavi G., Rao A., Fischer A., Feske S. STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. New England Journal of Medicine 2009, 360:1971-1980.
34. Platz K.P., Mueller A.R., Jonas S., Blumhardt G., Bechstein W.O., Lobeck H., Neuhaus H.L. Toxicity versus rejection-or why conversions between cyclosporine A and FK506 were performed after liver transplantation. Clinical Transplantation 1995, 9:146-154.
35. 2+ channel function. Journal of Cell Biology 2005, 169:435-445.
36. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:15545-15550.
37. 2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 channel activity. Molecular Pharmacology 2006, 69:1413-1420.
38. 2+ entry. Science 2006, 312:1220-1223.
39. Wulff H., Beeton C., Chandy K.G. Potassium channels as therapeutic targets for autoimmune disorders. Current Opinion in Drug Discovery and Development 2003, 6:640-647.
40. + channel, IKCa1: a potential immunosuppressant. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:8151-8156.
41. Yoshino T., Ishikawa J., Ohga K., Morokata T., Takezawa R., Morio H., Okada Y., Honda K., Yamada T. YM-58483, a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models. European Journal of Pharmacology 2007, 560:225-233.
42. 2+ store to the plasma membrane. Nature 2005, 437:902-905.
43. Zhang W., Huang R.S., Duan S., Dolan M.E. Gene set enrichment analyses revealed differences in gene expression patterns between males and females. In Silico Biology 2009, 9:55-63.
44. 2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2. Journal of Biological Chemistry 2004, 279:12427-12437.